2-AG	2-arachidonoylglycerol
5HT1A	5-hydroxytryptamin
ACE2	Angiotensin-converting enzyme 2
AD	Alzheimer’s disease
AEA	Anandamide
AIDS	Acquired immunodeficiency syndrome
AJA	Ajulemic acid
Ang 1-7	Angiotensin 1-7
Ang II	Angiotensin II
ART	Antiretroviral therapy
cAMP	Cyclic adenosine monophosphate
CB1	Cannabinoid receptor 1
CB2	Cannabinoid receptor 2
CBC	Cannabichromene
CBD	Cannabidiol
CBG	Cannabigerol
CBM	Cannabinoid-based medicine
CBN	Cannabinol
CNS	Central nervous system
COVID-19	Coronavirus disease 19
CUD	Cannabis use disorder
CYP	Cytochrome P450
DAGL	Diacylglycerol lipase
EAE	Encephalomyelitis
EB	Epidermolysis bullosa
EC	Endocannabinoid
ECS	Endocannabinoid system
ERK	Extracellular signal-regulated kinases
FAAH	Fatty acid amide hydrolase
GPCR55	G-protein-coupled receptor 55
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
HIV-SN	HIV-associated sensory neuropathy
LGS	Lennox–Gastaut syndrome
MAGL	Monoacylglycerol lipase
MAPK	Mitogen-activated protein kinase
MS	Multiple sclerosis
NAPE-PLD	N-acyl-phosphatidylethanolamine-specific phospholipase D
NAT	N-acyltransferase
NMS	Non-motor symptoms
NNT	Necessary number for treatment
PEA	Palmitoylethanolamide
PI	Protease inhibitor
PI3K	Phosphoinositide 3-kinase
PPARs	Peroxisome proliferator-activated receptors
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
SIV	Simian immunodeficiency virus
SNc	Substantia nigra pars compacta
THCV	Tetrahydrocannabivarin
TMPRSS2	Transmembrane of serine protease 2
TRP	Transient receptor potential
TRPA1	Transient receptor potential cation channel, subfamily A, member 1
TRPV1	Transient receptor potential cation channel, subfamily V, member 1
TRPV2	Transient receptor potential cation channel, subfamily V, member 2
UGP	UDP glucuronosyltransferase
UGT	5′-diphosphoglucuronosyltransferase
Δ9-THC or THC-Δ9 Delta-9-tetrahydrocannabinol